4.4 Article

Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway

Journal

DERMATOLOGY
Volume 237, Issue 2, Pages 166-178

Publisher

KARGER
DOI: 10.1159/000512930

Keywords

Psoriasis; Topical management; Fixed combination; Corticosteroids; Calcineurin inhibitors; Vitamin D-3 analogues

Categories

Funding

  1. LEO Pharma, Switzerland

Ask authors/readers for more resources

Topical treatment is crucial for the successful management of plaque psoriasis, with treatment goals defined together with the patient being crucial for treatment adherence. Swiss dermatologists provide current treatment options and tailored recommendations for specific areas through an expert opinion paper.
Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choice of a suitable topical treatment, the formulation matters and not just the active substances. This expert opinion paper was developed via a non-structured consensus process by Swiss dermatologists in hospitals and private practices to illustrate the current treatment options to general practitioners and dermatologists in Switzerland. Defining treatment goals together with the patient is crucial and increases treatment adherence. Patients' personal preferences and pre-existing experiences should be considered and their satisfaction with treatment and outcome regularly assessed. During the induction phase of classical mild-to-moderate psoriasis, the fixed combination of topical calcipotriol (Cal) 50 mu g/g and betamethasone dipropionate (BD) 0.5 mg/g once daily is frequently used for 4-8 weeks. During the maintenance phase, a twice weekly (proactive) management has proved to reduce the risk of relapse. Of the fixed combinations, Cal/BD aerosol foam is the most effective formulation. However, the individual choice of formulation should be based on a patient's preference and the location of the psoriatic plaques. Tailored recommendations are given for the topical management of specific areas (scalp, facial, intertriginous/genital, or palmoplantar lesions), certain symptoms (hyperkeratotic or hyperinflammatory forms) as well as during pregnancy or a period of breastfeeding. As concomitant basic therapy, several emollients are recommended. If topical treatment alone does not appear to be sufficient, the regimen should be escalated according to the Swiss S1-guideline for the systemic treatment of psoriasis. (c) 2021 The Author(s) Published by S. Karger AG, Basel

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available